Today: 2 July 2026
Browse Category

NYSE:LLY 28 October 2025 - 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum and ongoing institutional and retail interest. Eli Lilly shares closed around $1,092.4 on Tuesday, up just over 2% from Monday’s close near $1,070. That move extends a powerful multi-week rally and keeps the stock very close to its new 52‑week and all‑time high area around $1,095. Investing.com
25 November 2025
··
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly and Company remains one of the most closely watched stocks on Wall Street today as it trades just below the historic $1 trillion valuation it briefly reached on Friday, while fresh analyst upgrades, new obesity‑drug data and a major setback for rival Novo Nordisk’s Alzheimer’s program dominate the news cycle. Reuters+1 As of around late morning U.S. time on Monday, November 24, 2025, Eli Lilly shares are trading near $1,069.56, up about $9.86 on the session, a gain of roughly 0.9%. The stock has ranged between $1,000.76 and $1,074.01 so far today, reflecting ongoing volatility as investors digest both macro headlines and company‑specific news.
24 November 2025
·
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly’s stock is entering the new week as one of the most closely watched names on Wall Street. As of this weekend, LLY is trading near $1,060 per share, valuing the company at roughly $1 trillion, after becoming the first drugmaker ever to join the trillion‑dollar market‑cap club. Reuters At the same time, new headlines today highlight rising institutional ownership, aggressive analyst upgrades, and an emerging GLP‑1 price war that could reshape the economics of the obesity drug market Eli Lilly currently dominates.
23 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly heads into the weekend of November 22, 2025, sitting near record highs and fresh off becoming the first drugmaker ever to join the $1 trillion market‑cap club. A powerful combination of blockbuster obesity drugs, new access deals with the U.S. government and employers, and bullish analyst sentiment is keeping LLY at the center of Wall Street’s attention. Reuters+1 Below is a full look at what’s moving Eli Lilly stock today and what it could mean for investors watching LLY.
22 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

US Stock Market Today, November 22, 2025: Wall Street Ends a Wild Week Higher as Fed Cut Bets Rise and AI Rally Shows Cracks

After one of the rockiest stretches since spring, the US stock market heads into the weekend bruised but not broken. A powerful rally on Friday, November 21, 2025, pushed the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite solidly higher, even as all three benchmarks still finished the week in the red. AP News+1 On Saturday, November 22, investors are digesting a confusing mix of signals:
22 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 As of 00:40 UTC on Nov. 15, LLY is ~$1,025. The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the $920–$970B range, reflecting price swings and share count. On trailing metrics the stock trades near 50x earnings; on Lilly’s 2025 EPS guide midpoint, the forward P/E is ~44x. That premium embeds continued GLP‑1 scale‑up and pipeline options. Lightyear
15 November 2025
·
Netflix’s 10-for-1 Stock Split Arrives Monday: What NFLX Investors Need to Know Today – and Why Eli Lilly Could Be Next

Netflix’s 10-for-1 Stock Split Arrives Monday: What NFLX Investors Need to Know Today – and Why Eli Lilly Could Be Next

Netflix’s long-awaited 10‑for‑1 stock split is now entering its crucial final stage. After today’s market close, existing shareholders will receive nine additional shares for every one they already own, with split‑adjusted trading set to begin on Monday, November 17.Netflix+2Nasdaq+2 At the same time, Wall Street is buzzing about Eli Lilly, whose four‑digit share price and explosive growth have many analysts suggesting it could be the next mega‑cap stock to announce a split.Appreciate Wealth+3Barron's+3Barron's+3
14 November 2025
··
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc., the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy.GlobeNewswire+1 In a press release and accompanying SEC Form 8‑K filed Thursday, Mangoceuticals said it has launched two integrated programs — MangoRx Direct and PeachesRx Direct — built around official access to GLP‑1 obesity drugs from Eli Lilly and Novo Nordisk.GlobeNewswire+2SEC+2
13 November 2025
····
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones set a new record on Nov. 11, 2025, while the Nasdaq slipped as Nvidia fell after SoftBank disclosed a $5.8B stake sale. Europe rallied on rising BoE rate‑cut bets and Vodafone’s first dividend hike in years. Here’s what moved markets and what to watch before Thursday’s CPI. Wall Street ended mixed: a record‑setting Dow and firmer S&P 500 contrasted with a softer Nasdaq, reflecting rotation out of richly valued AI names and into large‑cap healthcare. Health care led sector gains with Eli Lilly, Johnson & Johnson, and AbbVie up more than 2% each, while semiconductors and AI‑adjacent names lagged. Reuters
11 November 2025
········
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind. Beyond the single asset, Lilly secures platform access—vector and riboswitch technologies—that could seed a broader ophthalmology pipeline. Strategically, this builds on Lilly’s Adverum acquisition in October for an intravitreal wet AMD gene therapy candidate, signaling a deliberate expansion into vision care alongside its metabolic crown jewels. BioPharma Dive+2Reuters+2
10 November 2025
······
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com. This abrupt shift in sentiment has been fueled by multiple challenges converging at once. Intensifying competition, pricing pressures, and even copycat drugs have combined to erode the previously sky-high expectations for Novo’s obesity franchisestocktwits.comreuters.com. The result: what was recently a steady success story has turned into what one analyst called a “chaotic” battle to defend Novo’s weight-loss drug leadershipstockanalysis.comstockanalysis.com. Investors, who bid Novo’s market capitalization to record levels in 2023, are now reeling from a string of disappointing updates in 2025.
5 November 2025
···
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

As of Oct. 31 close, Eli Lilly was around $862–864 Stockanalysis Marketbeat. That’s up ~9–10% from early October Nasdaq. Trading volumes have been heavy, and LLY remains near its 52-week high Marketbeat. MarketBeat notes LLY’s 50-day moving average is ~$780 Marketbeat, reflecting the recent surge. Institutional ownership is high and sentiment is bullish. Expert Take: Bahl & Gaynor portfolio manager Kevin Gade praises the quarter, calling the surge in international Mounjaro sales “a fantastic factor” and a driver of the beat-and-raise results Reuters. Cantor Fitzgerald’s Carter Gould says Lilly delivered “the strongest Q3 earnings report [he’d] seen so far” Reuters. These comments underscore robust product demand.
2 November 2025
·
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year. The stock then saw a mid-month wobble. On Oct. 16 President Trump announced plans to cut the cost of GLP-1 weight-loss drugs like Wegovy to around $150 per month ts2.tech. Investors feared this could extend to all GLP-1 medications, including Lilly’s Mounjaro and Zepbound. LLY shares fell roughly 4% on that day ts2.tech, dipping into the high-$700s. This episode highlighted a new risk: while demand for Lilly’s obesity and diabetes drugs is exploding, potential drug-price legislation or negotiations could affect profitability.
30 October 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly’s stock has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly. Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai. Over the past 12 months LLY has significantly outperformed the broader market, in large part thanks to its GLP-1 diabetes/obesity franchise. Wall Street now assigns it a Moderate Buy consensus; 25 analysts have issued price targets totaling an average ~$938.61marketbeat.com. A Nasdaq/Fintel report noted an average one-year target near $904nasdaq.com. In short, most experts see further upside, though Lilly’s high valuation leaves little margin for error.
30 October 2025
···
2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

Stock markets around the world are on fire heading into the final days of October 2025. Hong Kong’s Hang Seng Index – up about 34–35% so far this year – is the planet’s best-performing major index Advisorperspectives. After a brutal multi-year slump, Hong Kong’s market came roaring back thanks to ultra-cheap valuations and China’s post-pandemic stimulus. Investors flooded into undervalued Chinese tech and consumer stocks, driving a dramatic rebound. As a result, the Hang Seng has erased its losses from prior years and is flirting with three-year highs Dividendtitan Dividendtitan. “The market was clearly undervalued… confidence returned, money flowed in again,” one Hong Kong analyst noted of 2025’s turnaround Dividendtitan. A series of catalysts fueled the surge – from Beijing’s big economic stimulus packages to breakthroughs in Chinese AI technology and blockbuster movie releases energizing consumer sentiment Dividendtitan Dividendtitan. Even a mid-October trade scare barely dented the momentum – the Hang Seng Volatility Index spiked, but investors quickly bought the dip, betting that U.S.-China tensions would ease Reuters Reuters. As of this week, Hong Kong stocks remain on a tear, buoyed by renewed trade-deal hopes and expectations of further Chinese policy support. The Hang Seng’s resilience – up ~30%+ in
29 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····
1 … 9 10 11 12 13

Stock Market Today

  • Cramer’s Top 10: Jobs Miss, Upgrades for Palantir and Airlines, OpenAI’s Government Plan
    July 2, 2026, 9:20 AM EDT. Jim Cramer's July 2 watchlist points to a lighter-than-forecast June jobs report-nonfarm payrolls up just 57,000, well below the 115,000 expected. That pushed Treasury yields lower and futures up. OpenAI is reportedly offering the U.S. government a 5% stake to let it in on AI gains. Palantir saw DA Davidson boost the stock to buy, setting a target for 40% upside. Nvidia is rolling out a model where AI startups get compute power in exchange for a piece of revenue. Meta laid out fresh plans for cloud AI. Honeywell Aerospace, Delta, and United picked up upgrades as supply and fuel costs improved. DuPont's price target saw a small bump.
Go toTop